Immune cells trained to fight advanced throat cancer in new trial
NCT ID NCT05261750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a personalized immune cell therapy (dendritic cells) is safe and can help control advanced nasopharyngeal cancer. The treatment uses the patient's own immune cells and donor cell secretions to boost the body's cancer fight. The study involves 15 adults whose cancer did not fully respond to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PT Prodia StemCell Indonesia
Jakarta, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sharper radiation boost aims to tackle head and neck cancers that return
- Mouth rinse could ease painful radiation side effects for head and neck cancer patients
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- Could less radiation be just as good for some throat cancers?
- New drug cocktail aims to beat back aggressive throat cancer
- Early jaw exercises may prevent lockjaw in cancer patients